Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) EVP Sells $333,787.50 in Stock

Ionis Pharmaceuticals, Inc. (NASDAQ:IONSGet Free Report) EVP Patrick R. O’neil sold 6,450 shares of the company’s stock in a transaction that occurred on Thursday, January 25th. The stock was sold at an average price of $51.75, for a total value of $333,787.50. Following the transaction, the executive vice president now directly owns 46,802 shares in the company, valued at $2,422,003.50. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Ionis Pharmaceuticals Stock Performance

Shares of IONS opened at $51.90 on Wednesday. The company has a current ratio of 6.39, a quick ratio of 6.33 and a debt-to-equity ratio of 4.06. The company has a market capitalization of $7.45 billion, a price-to-earnings ratio of -18.08 and a beta of 0.47. The stock has a 50 day moving average of $50.75 and a 200 day moving average of $45.91. Ionis Pharmaceuticals, Inc. has a 12 month low of $32.69 and a 12 month high of $54.44.

Ionis Pharmaceuticals (NASDAQ:IONSGet Free Report) last issued its quarterly earnings results on Thursday, November 2nd. The company reported ($1.03) EPS for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.02). The business had revenue of $144.00 million for the quarter, compared to analysts’ expectations of $139.42 million. Ionis Pharmaceuticals had a negative net margin of 66.34% and a negative return on equity of 90.50%. As a group, sell-side analysts forecast that Ionis Pharmaceuticals, Inc. will post -3.05 earnings per share for the current year.

Hedge Funds Weigh In On Ionis Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the company. HealthInvest Partners AB bought a new position in Ionis Pharmaceuticals during the fourth quarter valued at $1,226,000. Strs Ohio bought a new position in Ionis Pharmaceuticals during the fourth quarter valued at $1,253,000. Friedenthal Financial bought a new position in Ionis Pharmaceuticals during the fourth quarter valued at $720,000. Tennessee Valley Asset Management Partners bought a new position in Ionis Pharmaceuticals during the fourth quarter valued at $34,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Ionis Pharmaceuticals by 352.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 16,598 shares of the company’s stock valued at $840,000 after purchasing an additional 12,928 shares during the period. 93.86% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms recently weighed in on IONS. Piper Sandler upped their price target on Ionis Pharmaceuticals from $60.00 to $62.00 and gave the stock an “overweight” rating in a research note on Thursday, January 18th. Needham & Company LLC reaffirmed a “buy” rating and set a $60.00 price target on shares of Ionis Pharmaceuticals in a research note on Tuesday, December 19th. William Blair reaffirmed an “outperform” rating on shares of Ionis Pharmaceuticals in a research note on Monday, November 13th. Royal Bank of Canada increased their price objective on Ionis Pharmaceuticals from $65.00 to $70.00 and gave the stock an “outperform” rating in a research note on Friday, January 26th. Finally, Stifel Nicolaus increased their price objective on Ionis Pharmaceuticals from $45.00 to $50.00 and gave the stock a “hold” rating in a research note on Monday, December 18th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Ionis Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $49.43.

Read Our Latest Report on IONS

Ionis Pharmaceuticals Company Profile

(Get Free Report)

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.

See Also

Insider Buying and Selling by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.